Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

535
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
535
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

639
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
639
Glaucoma: Overview01:25

Glaucoma: Overview

712
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
712
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

1.9K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term efficacy of neural circuit blockade for treating blepharospasm: a retrospective case series study.

Frontiers in neurology·2026
Same author

Clinical risk factors for recurrence in adult-onset myelin oligodendrocyte glycoprotein antibody-associated optic neuritis.

BMC ophthalmology·2026
Same author

Optimized AAV5-RPGR ORF15 Gene Therapy Rescues Photoreceptor Structure and Function in X-Linked Retinitis Pigmentosa Mouse Model.

American journal of ophthalmology·2026
Same author

JAK-STAT signaling pathway in cancer: from molecular mechanisms to clinical intervention.

Molecular cancer·2026
Same author

Discovery and Validation of Lung Cancer Biomarkers Based on Proteomic Analysis of Bronchoalveolar Lavage Fluid from the Self-Controlled Pulmonary Lobes.

Journal of proteome research·2026
Same author

Paraneoplastic neuromyelitis optica spectrum disorder with dual AQP4-IgG and CRMP5 antibodies following thymectomy: a case report.

Frontiers in neuroscience·2026

Related Experiment Video

Updated: Sep 3, 2025

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
09:29

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

Published on: August 21, 2017

11.6K

Update on glial antibody-mediated optic neuritis.

Honglu Song1,2, Huanfen Zhou1, Shihui Wei3

  • 1Senior Department of Ophthalmology, The Chinese People's Liberation Army General Hospital, Beijing, China.

Japanese Journal of Ophthalmology
|July 27, 2022
PubMed
Summary

Glial autoantibodies like AQP4-IgG and MOG-IgG are key biomarkers for diagnosing and managing optic neuritis (ON). Screening for these antibodies improves treatment and understanding of ON, especially atypical forms.

Keywords:
Aquaporin-4Myelin oligodendrocyte glycoproteinNeuromyelitis optica spectrum disorderOptic neuritis

More Related Videos

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients
12:23

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients

Published on: April 14, 2014

14.2K
An Ex Vivo Explant Model for Studying Glial Interactions in the Mouse Retina
09:46

An Ex Vivo Explant Model for Studying Glial Interactions in the Mouse Retina

Published on: July 15, 2025

635

Related Experiment Videos

Last Updated: Sep 3, 2025

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
09:29

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

Published on: August 21, 2017

11.6K
Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients
12:23

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients

Published on: April 14, 2014

14.2K
An Ex Vivo Explant Model for Studying Glial Interactions in the Mouse Retina
09:46

An Ex Vivo Explant Model for Studying Glial Interactions in the Mouse Retina

Published on: July 15, 2025

635

Area of Science:

  • Neuroimmunology
  • Ophthalmology

Background:

  • Optic neuritis (ON) causes vision loss, particularly in young adults.
  • Glial autoantibodies, aquaporin-4 immunoglobulin (AQP4-IgG) and myelin oligodendrocyte glycoprotein immunoglobulin (MOG-IgG), are crucial biomarkers for ON.
  • Understanding ON has evolved with the identification of these antibodies.

Purpose of the Study:

  • To review the diagnosis and management of glial antibody-mediated optic neuritis.
  • To highlight the role of AQP4-IgG and MOG-IgG in understanding and treating ON.
  • To discuss emerging targeted immunotherapies for ON.

Main Methods:

  • Literature review of optic neuritis and glial autoantibodies.
  • Analysis of diagnostic criteria and treatment strategies.
  • Synthesis of current research on AQP4-IgG and MOG-IgG in ON.

Main Results:

  • Glial autoantibodies (AQP4-IgG, MOG-IgG) are vital for diagnosing atypical ON.
  • Antibody screening aids in patient management and follow-up.
  • Targeted immunotherapies show promise for treating ON.

Conclusions:

  • Glial antibody testing is essential for accurate ON diagnosis and personalized treatment.
  • Further research into NMOSD and MOGAD pathogenesis will drive new therapies.
  • Effective management of ON relies on identifying and targeting specific autoantibodies.